SUPPLEMENTARY FILE

Supplementary Table 1. Additional Safety Endpoints by Treatment Group[a]

	All Patients in OLE (N=343)	
Change From Baseline to Week 80, [Direction of Improvement: +/–] Patients assessed at Week 80: n=66	**Mean**	**SD**
UPDRS: Motor [–]	–0.7	8.2
BARS [–]	–0.8	2.1
HADS: Anxiety [–]	–0.2	3.5
HADS: Depression [–]	0.7	3.4
ESS [–]	–0.0	4.4
MoCA [+]	0.1	2.4

C-SSRS	**Overall Post-baseline**		**At Screening**			
	All Patients in OLE (n=342)		**Prior Placebo (n=111)**		**Prior Deutetrabenazine (n=232)**	
	n	**%**	**n**	**%**	**n**	**%**
Suicidal ideation, n (%)	16	5	24	22	58	25
Suicidal behavior, n (%)	2	<1	15	14	46	20
Self-injurious behavior without suicidal intent, n (%)	0	0	4	4	7	3

[a]BARS, Barnes Akathisia Rating Scale; BL, baseline; C-SSRS, Columbia Suicide Severity Rating Scale; ESS, Epworth Sleepiness Scale; HADS, Hospital Anxiety and Depression Scale; MoCA, Montreal Cognitive Assessment; OLE, open-label extension; SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale.

Supplementary Table 2. Exposure-Adjusted Incidence Rates of Other AEs of Special Interest[a]

	Placebo (n=131)[a]			Deutetrabenazine											All Patients in OLE (N=343)		
				12 mg/day (n=74)			24 mg/day (n=73)			36 mg/day (n=74)			ARM-TD (n=58)					
	EAIR	n	P-Y	EAIR	n	P-Y	EAIR	n	P-Y	EAIR	n	P-Y	EAIR	n	P-Y	EAIR	n	P-Y
Depression[b]	0.04	1	28.5	0.06	1	16.0	0.20	3	15.3	0.13	2	15.2	0	0	12.4	0.09	27	314.0
Suicidality	0.04	1	28.5	0	0	16.0	0.13	2	15.6	0.07	1	15.4	0	0	12.4	0.02	7	328.6
Akathisia and restlessness	0	0	28.6	0.06	1	15.9	0.06	1	15.6	0.06	1	15.5	0.25	3	12.2	0.02	5	328.1
Somnolence and sedation	0.34	9	26.7	0	0	16.0	0.06	1	15.6	0.27	4	14.8	0.81	9	11.1	0.11	34	308.0
Parkinsonism	0.04	1	28.4	0	0	16.0	0	0	15.7	0.07	1	15.3	0.08	1	12.3	0.05	15	319.8

[a]AE, adverse event; EAIR, exposure-adjusted incidence rate; n, number of patients; P-Y, patient-years.

[a] n pooled from the AIM-TD (placebo n=72) and ARM-TD (placebo n=59) studies; [b] Includes dysthymic disorder.

Supplementary Table 3. Patient-Reported Outcomes[a]

Secondary Efficacy Assessments		
	n	**%**
PGIC at Week 80		
Patients assessed at Week 80: n=65		
Treatment success[a]	44	68
	Mean	**SE**
mCDQ-24 (Direction of Improvement: –)		
Patients assessed at Week 54: n=144		
Total Score Change	–5.5	1.2
Subdomains Change		
ADL	–5.8	1.6
Emotional	–3.4	1.7
Pain	–7.3	1.5
Social	–3.5	1.3
Stigma	–7.3	1.7

[a]PGIC treatment success is defined as a rating of "Much Improved" or "Very Much Improved"; ADL, activities of daily living; mCDQ-24, Modified Craniocervical Dystonia Questionnaire; PGIC, Patient Global Impression of Change; SE, standard error.